Research published in @BMCMedicine reports that, among a sample of patients from China, selinexor combined with a low dose of dexamethasone provided clinical benefit to patients with relapsed/refractory multiple myeloma. https://t.co/FiXCVNy7KU
A phase II, single-arm study into Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple #myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor. Read it here: https://t.co/ggsFI4GOI6 htt
Research published in @BMCMedicine reports that, among a sample of patients from China, selinexor combined with a low dose of dexamethasone provided clinical benefit to patients with relapsed/refractory multiple myeloma. https://t.co/FiXCVNy7KU
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study #lymphoma #lymsm https://t.co/UkeVv2Ggrs